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Abstract: Illicit drug use in HIV-infected patients can be linked to impairment of physical and mental health, low health-
related quality of life, and suboptimal adherence to HIV treatment. This study aimed to evaluate the correlation of self-
report illicit drug use, urinalysis for cocaine and cannabis metabolites, and severity of dependence among HIV-infected 
patients on antiretroviral therapy (ART) in a treatment center in Brazil. Four hundred and thirty-eight outpatients of an 
HIV referral center were interviewed and assessed for drug use (lifetime, last year and last month). Urinalysis was 
performed to detect the presence of cocaine and cannabis metabolites in urine samples. Overall agreement between self-
report and urinalysis was almost 68% for cannabis and higher than 85% for cocaine. Positive urinalysis was significantly 
associated with more than once a week cannabis (p < .0001) and cocaine (p < .0001) use during the last-month. Severity 
of Dependence Scale (SDS) properly predicted positive cocaine urinalysis results (area under the curve [AUC] = .81, p = 
.0001). Frequency of cannabis and cocaine use, SDS score degree and positive urinalysis for both drugs were correlated. 
Our findings suggest that positive self-report is a reliable predictor of positive urine sample both for cannabis and cocaine, 
but since the agreement was not perfect, there is a role for urine drug screening in the care of patients with HIV-related 
conditions. 
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INTRODUCTION 
 Illicit drug use is common among HIV-infected 
individuals. Approximately half of a national sample of 
HIV-infected Americans reported a history of substance 
abuse [1]. In a large study (611 patients from 8 clinical care 
sites) in the United States, the most common drugs used 
were marijuana (12%) and crack-cocaine (5%). Seven 
percent of them reported polysubstance use [2]. 
 In Brazil, there are no consistent data about the pre-
valence of drug use in HIV positive individuals. Moreover, 
data about the impact of drug use in HIV treatment in Brazil 
is still scarce. In two studies, lifetime drug use was referred 
by 28 and 58% of the sample [3, 4]. 
 Illicit drug use in HIV-infected patients can be linked to 
impairment of physical and mental health, low access to 
care, low health-related quality of life, suboptimal adherence 
to HIV treatment and poorer health outcomes than other HIV 
risk groups [5- 8]. 
 In clinical settings, patients’ self-report of drug use may 
not accurately correspond to their actual drug use behavior 
[9]. In order to increase the reliability of the assessment of 
substance use, various authors have recommended the use of 
urinalysis in addition to self-report, especially among 
populations at high risk for drug use [10-14]. 
 Although biometric measures of substance use (e.g., 
urinalysis) may be perceived as a more accurate assessment  
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of drug use compared to self-report, they also have limitat-
ions. First, the biometric measure uses a static snapshot of 
the biological state to infer a more general consumption level 
over a period of time [15]. The second limitation is that 
detection time windows for drugs in biological specimens 
are inexact, depending on quantity and frequency of use, 
route of administration, cutoff of the analytic technique, and 
characteristics of individuals such as metabolic rates [16]. 
 Although self-report and urinalysis each have some 
limitations, their combination may improve the detection rate 
of drug use. Based on this premise, the present study aims to 
assess the relationship of urinalysis and self-report for 
cocaine and cannabis use among HIV-infected patients on 
antiretroviral therapy (ART). 
MATERIAL AND METHODS 
Study Subjects 
 This study was conducted at the HIV treatment center 
affiliated with the School of Medicine, University of São 
Paulo, Brazil. Since 1994, the center has been providing 
multidisciplinary care on HIV/AIDS. High complexity pati-
ents, with a wide range of physical problems, psychological 
and social consequences of HIV infection, are followed 
accordingly to the Brazilian Ministry of Health protocols. 
 In this service, 32 infectologists assess 8 patients per day. 
From the daily patients’ list, the first 5 patients were invited 
to participate in the study. This procedure was done daily 
until the sample was completed. 
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 This is a secondary data analysis of data generated by a 
larger study that evaluated the adherence to ART. The 
inclusion criteria reflect this larger study [17]. 
 Inclusion criteria were: age between 18-60 years, being 
on antiretroviral therapy, having HIV-related laboratorial 
data (CD4, cell count and viral load) within the last three 
months preceding the interview, and having a contact phone 
number. 
 Exclusion criteria were: clinical diagnosis of dementia or 
less than 24 points on the Mini-Mental State Examination 
(MMSE) [18]. 
 The final sample included 438 patients (Fig. 1). 
Interviews 
 Patients answered a questionnaire addressing lifetime, 
last-year and last-month drug use. Use during the last-month 
was further classified as less than once a week or use at least 
once a week. Only marijuana and cocaine use were assessed 
as they are the most common illicit drugs in Brazil. All the 
patients who reported any use during the last-year also 
answered the Severity of Dependence Scale (SDS) [19]. 
 The SDS is a five-item questionnaire, each item scored 
on a four-point scale (from 0 to 3). This questionnaire was 
designed to measure the severity of dependence specifically 
related to self-evaluated feelings of impaired control over the 
use, preoccupation and anxiety towards drug use. The total 
SDS scores range from 0 to 15, with higher scores indicating 
a more severe level of dependence. 
 All interviews were conducted by trained psychiatrists or 
psychologists. 
Urinalysis 
 Each patient was asked to provide a urine sample following 
the interview. These samples were submitted firstly to 
qualitative analysis of pH, creatinine concentrations, physical 
characteristics, and the presence of adulterants. Then, screening 
immunoassay tests for the presence of cannabis (delta-9-
tetrahydrocannabinol-9-carboxylic acid, THCA) and cocaine 
(Benzoylecognine) metabolites were performed. Positive 
screening results underwent Gas Chromatography/Mass 
Spectrometry (GC/MS) confirmatory analysis. All procedures 
of urinalysis were performed by the College of Pharmaceutical 
Sciences and Toxicology, University of São Paulo. Screening 
and confirmatory cutoffs for cannabis and cocaine were in 
accordance to the Mandatory Guidelines for Federal Workplace 
Drug Testing Programs [20]. Screening cutoff at immunoassay 
tests was 50 nanograms per milliliter (ng/mL) for THCA and 
300 ng/mL for benzoylecognine, with confirmatory GC/MS 
cutoffs of 15 ng/mL and 150 ng/mL, respectively. 
Ethical Considerations 
 This study was approved by the Ethics in Research 
Committee of the Hospital das Clínicas, Medical School, 
University of São Paulo (Protocol number 654/05). All 
subjects included in the study gave written informed consent 
prior to their inclusion in the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Sample selection. 
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Statistical Analyses 
 Chi-square tests were used for associations between 
Urinalysis and Self-report. Self-report drug use was 
presented as a dichotomic (no/yes) variable for lifetime, last-
year and last-month use and as a three point variable (no 
use/less than once a week/once or more per week) for last-
month use. Receiver Operating Characteristic (ROC) curve 
analysis was used to correlate urinalysis and SDS scores. 
Areas under the ROC curve (AUC) with 95% confidence 
interval and p values < 0.05 were considered significant. 
Only patients who reported use during the last-year were 
included in the analysis. Pearson’s correlations were done to 
analyze results between the following variables: frequency 
of drug use according to the three point variable of drug use; 
SDS scores, categorized as 0 (SDS equal zero), 1 (SDS up to 
two point threshold) and 2 (SDS higher than 2); urinalysis 
categorized as 0 (negative urinalysis), 1 (cannabis or cocaine 
positive urinalysis) and 2 (both cannabis and cocaine 
positive urinalysis). For statistical analysis, only subjects 
with last-year drug use were considered. 
 Analyses were performed with SPSS-16 for Windows 
statistical software package. The level of statistical 
significance was set at  =.05. 
RESULTS 
 In discussing the results of the study, factors such as 
sociodemographic data, self-reports of substance use, drug 
use and urinalysis, degree of dependence according to SDS, 
and the correlation between frequency of drug use, SDS, and 
urinalysis must be reviewed and considered. 
Sociodemographic Data 
 Four hundred and thirty-eight patients were included in 
the study and were assessed between July of 2006 and 
January of 2007. Two hundred and twenty-six (51.6%) were 
males and the mean age was 41.7 years (SD = 8.1, range 19-
60). Almost 32% of the patients, (n = 139) lived with a 
partner and 299 (68%) lived alone. There were 331 patients 
(75.6%) who had up to eleven years of education and 107 
(24.4%) more than 11 years. Nearly 62% were currently 
working (n = 271) and 167 (38%) were retired or on medical 
leave. Mean annual income was US$ 11,056 (SD = 10,428; 
range 1,283 - 91,397). 
 Sexual transmission was identified as the most likely 
source of infection by 359 (82%) patients. Close to 2% (n = 
8) of the patients reported hemodialysis/transfusion as the 
most likely method of transmission and seventy-one (16%) 
patients did not know their mode of transmission. Sixteen 
patients reported lifetime injection drug use, but none 
associated this behavior to their HIV status. 
Self-Reports of Substance Use 
 Because drug use is an important variable in HIV 
treatment, it is important to learn a patient’s self-reported 
history of substance use. Lifetime drug use was reported by 
193 (44.1%) patients on ART, of which 180 (41.1%) 
reported having used cannabis (marijuana or hashish), 92 
(21.0%) cocaine and 87 (19.8%) both. 
 A total of 62 patients (14.2%) reported last-year drug use. 
The prevalence of cannabis, cocaine and both drugs use 
within the last-year was 10.3% (n = 45), 6.8% (n = 30) and 
3.9% (n = 17), respectively. 
 The prevalence of last-month drug use was 9.1% (n = 
40), being 7.8% for cannabis (n = 34), and 3.7% for cocaine 
(n = 16). Last-month use of both drugs was reported by 2.3% 
(n = 10) of the sample. Less than once a week use was 
reported by 12 cannabis users (35.3%) and by 10 cocaine 
users (62.5%); 64.7% (n = 22) and 37.5% (n = 6) reported 
more than once a week use of cannabis and cocaine, 
respectively. Daily use was reported only by cannabis users 
(29.3%, n = 10). 
Drug Use and Urinalysis 
 All the subjects of the study agreed to provide a urine 
sample. Associations between urinalysis and self-reported 
last-month use are shown in Table 1. Cannabis use once or 
more times per week in the last-month was significantly 
associated with a positive urinalysis (2 = 25.59, p < .0001). 
Positive cocaine urinalysis and once or more per week 
cocaine use during the last-month were also significantly 
associated (2 = 41.22, p < .0001). 
Table 1. Urinalysis Results for Cannabis and Cocaine 
Metabolites and Self-Report of Last Month Drug 
Use 
 
Urinalysis 
 
Positive Negative 
Total 
Last Month Cannabis Use 
No  1 (3.6) 27 (96.4) 28 (45.2) 
Less than once a week  1 (8.3) 11 (91.7) 12 (19.3) 
Once or more per week 14 (63.6)*  8 (36.4) 22 (35.5) 
Last Month Cocaine Use 
No  1 (2.2) 45 (97.8) 46 (74.2) 
Less than once a week  2 (20.0)  8 (80.0) 10 (16.1)  
Once or more per week  6 (100.0)*  0 (0.0)  6 (9.7) 
*p < 0.0001. 
 
 The disagreement between self-report and urinalysis 
involved a positive self-report and a negative urinalysis in 
most of the cases. Only on 2 cases such disagreement was 
between a negative self-report and a positive urinalysis. 
Severity of Dependence According to the Severity of 
Dependence Scale 
 For the purposes of this study, it was important to 
understand a patient’s severity of dependence on drugs and 
its impact on the results of urinalysis. ROC analysis showed 
that SDS properly differentiated positive from negative 
cocaine urinalysis results, the best cutoff being 6 (AUC = 
.81, p = .0001). Regarding cannabis, the SDS did not 
associate with the urinalysis as the 95% Confidence Interval 
for the AUC crossed the mark of 0.5, which is random 
correlation. 
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Correlation Between Frequency of Drug Use, SDS Scores 
and Urinalysis 
 Finally, frequency of cannabis and cocaine use and 
degree of dependence as measured by the SDS and positive 
urinalysis for both drugs were correlated, suggesting 
collinearity among the variables. There is no correlation 
between frequencies of each drug use (Table 2). 
DISCUSSION 
 The overall agreement on positive report between self-
report and urinalysis above 85% for cocaine use suggests 
that self-report is a quite reliable assessment of recent 
cocaine use. Such notion is reinforced by the fact that the 
discrepancies were between positive self-reports and 
negative urinalyses (the reported use was not confirmed by 
toxicological urinalysis). The same conclusion applies to 
cannabis as the overall agreement on positive report for 
cannabis was lower than to cocaine mainly because of 8 
clients with positive self-report and negative urinalysis. It is 
important to point out that subjects knew that they would be 
required to undergo a urine test. 
 However, the discrepancies between self-report and 
urinalysis can be explained by four hypotheses; (1) the 
clients have used the substance with minimal or no amounts 
of the active principle (fake or diluted); (2) the clients have 
used small quantities of the substance, rendering low levels 
of metabolites, below the detection threshold of the assay; 
(3) the time between substance use and the urine analysis 
was too long to detect the metabolites; (4) the clients 
provided false information about the consumption. This 4
th
 
hypothesis is quite unlikely as we cannot identify reasons or 
potential gains that patients would have to report use when 
such use did not actually happen. With the data from our 
study, the first three hypotheses are equally plausible. 
 It is noteworthy that the finding of positive self-report and 
negative urinalysis has also been reported in other samples. The 
methodological limitations of the urinalysis may have also 
played a role, although in the study reported by Harrison et al. 
[12], the screening and confirmatory cutoffs for cannabis 
metabolites (30 ng/mL and 5 ng/mL, respectively) were lower 
than those used in this study (50 ng/mL and 15 ng/mL). Such 
finding may also be explained by the influence of the timeframe 
utilized in different studies [21]. 
 Next, another finding was that the severity of dependence 
measured by the SDS was associated to positive urinalysis 
for cocaine, but not for cannabis. Considering that urinalysis 
is associated with quantity and recency of use (aspects not 
assessed by the SDS), such lack of association could indicate 
that those parameters are not as good indicators of severity in 
cannabis dependence as they may be in cocaine dependence. 
 Another consideration is that, along with substance use, 
one of the major matters of concern is the association of two 
or more substances. Findings of this study show that having 
two different metabolites in urine was correlated with 
frequency and severity of drug use and degree of 
psychological impairment measured by the SDS. The 
positive relationship between psychological impairment and 
number of substances used has already been reported [22]. 
 Finally, as noted previously, all of the subjects knew that 
their urine would be tested. This fact may have stimulated a 
true self-report use of drugs. In this context, urinalysis did 
not improve drug detection rate. 
 In conclusion, considering that drug use is an important 
variable in HIV treatment, the findings of this study suggest 
that HIV treatment centers may offer random urine drug 
screening to increase the accuracy of the information about 
drug use. Considering that patients’ self-report can be 
enhanced by knowing that such tests can be used at any time 
as part of the treatment program, we would suggest random 
selection test rather than testing all patients as such method 
would be cost-saving. 
 Some limitations of the present study must be discussed. 
Initially, the coercive power of the urinalysis on the intention 
to disclose drug use might bias self-reports. According to the 
protocol of the present study, the participants knew that their 
urine was going to be tested. Although such knowledge did 
not influence their intention to participate, since no patient 
refused to enter into the present study after reading the study 
protocol, it might have influenced their willingness to report 
substance use. 
 Although the sample was similar to the population 
treated in the service [23], subjects were not randomly 
selected from all HIV patients in Brazil. Therefore, the 
results of this study can be generalized to the population of 
our center, but further generalization is limited to similar 
populations. 
CONCLUSION 
 Although self-report was overall more positive than 
urinalysis, knowing that a urine sample would be tested may 
have contributed to an open disclosure of drug use in the 
self-report. Given the relevance of this information on the 
Table 2. Correlations Among Frequency of Cannabis and Cocaine Last Month Use, SDS Scores and Positive Urinalysis Using 
Pearson’s r 
 
 Frequency of Last Month Cocaine Use Frequency of Last Month Cannabis Use SDS Positive Urinalysis 
Frequency of last month cocaine use 1 .004 .451* .454* 
Frequency of last month cannabis use  1 .576* .428** 
SDS   1 .531* 
Positive Urinalysis    1 
SDS = Severity of Dependence Scale. 
*p < 0.01. 
** p < 0.05. 
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treatment of this population, we suggest a random use of 
urinalysis in the care of patients with HIV-related conditions. 
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